Clinical Trial Update: Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus. [Phase 1]

View source ↗

Summary

This Phase 1 trial reports safety data for PiggyBac transposon–based CD-19 CAR T-cells in patients with refractory systemic lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• PiggyBac CD-19 CAR T-cell therapy (CD19-targeted CAR T cells using PiggyBac transposon)

Snippet

Sponsor: Chulalongkorn University | Conditions: SLE (Systemic Lupus) | Phase 1 | Status: COMPLETED